{"disease":{"id":"respiratory-syncytial-virus-rsv","name":"respiratory syncytial virus rsv"},"drugs":{"marketed":[{"drug_id":"nirsevimab","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beyfortus","generic_name":"NIRSEVIMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"RSV","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"beyfortus","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beyfortus","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV-associated hospitalization due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in young children with a history of premature birth or bronchopulmonary dysplasia.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"nirsevimab-alip","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BEYFORTUS","generic_name":"NIRSEVIMAB-ALIP","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"rsv-prefusion-f-protein-based-vaccine","indication_name":"Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSV prefusion F protein-based vaccine","generic_name":"rsv-prefusion-f-protein-based-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Respiratory syncytial virus fusion (F) protein","drug_class":"Viral protein subunit vaccine","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05622331","title":"Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden","phase":"","overall_status":"COMPLETED","enrollment_count":1100000,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07249320","title":"Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39456,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07272434","title":"Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"MAXVAX Biotechnology Limited Liability Company","has_results":false},{"nct_id":"NCT06207929","title":"Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections","phase":"","overall_status":"COMPLETED","enrollment_count":18157,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT06229444","title":"Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI","phase":"NA","overall_status":"COMPLETED","enrollment_count":17043,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT03627572","title":"RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT06185647","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","phase":"","overall_status":"COMPLETED","enrollment_count":4924,"lead_sponsor_name":"Hôpital Armand Trousseau","has_results":false},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT06521944","title":"RSV Vaccine Pregnancy Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2062,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT03698084","title":"RESCEU: Defining the Burden of RSV Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05277298","title":"Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"National Institute for Communicable Diseases, South Africa","has_results":false},{"nct_id":"NCT06392451","title":"LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"DiaSorin Molecular LLC","has_results":false},{"nct_id":"NCT05842967","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":885,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07516418","title":"Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":570,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06890416","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":526,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06642558","title":"Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":522,"lead_sponsor_name":"MAXVAX Biotechnology Limited Liability Company","has_results":false},{"nct_id":"NCT06473519","title":"A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":453,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02289820","title":"A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT04925310","title":"Infection With Respiratory Syncytial Virus in Infants","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT02298179","title":"A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06077149","title":"Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"University of Rochester","has_results":true},{"nct_id":"NCT07106918","title":"A Clinical Trial of SIBP-A16 Injection in Healthy Adults","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Shanghai Institute Of Biological Products","has_results":false},{"nct_id":"NCT06851806","title":"Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07543380","title":"A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05900154","title":"A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07492706","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"MAXVAX Biotechnology Limited Liability Company","has_results":false},{"nct_id":"NCT06216093","title":"Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"EuBiologics Co.,Ltd","has_results":false},{"nct_id":"NCT04816721","title":"A Study to Evaluate EDP 938 Regimens in Children With RSV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Enanta Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT06881056","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","phase":"NA","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"West China Second University Hospital","has_results":false},{"nct_id":"NCT06442241","title":"A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Guangzhou Patronus Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06067191","title":"Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03916185","title":"Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02830932","title":"Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Vaxart","has_results":false},{"nct_id":"NCT02534350","title":"Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04225897","title":"A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02968173","title":"A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03236233","title":"A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Pulmocide Ltd","has_results":false},{"nct_id":"NCT07363837","title":"Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Shanghai Institute Of Biological Products","has_results":false},{"nct_id":"NCT03095495","title":"High Flow Nasal Cannula Therapy in Bronchiolitis : Early vs Rescue","phase":"NA","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Hamad Medical Corporation","has_results":false},{"nct_id":"NCT04748159","title":"Effects of Prone Positioning on Vital Parameters in Infants With Acute Bronchiolitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Luzerner Kantonsspital","has_results":false},{"nct_id":"NCT04896853","title":"Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"NextCell Pharma Ab","has_results":false},{"nct_id":"NCT04927793","title":"Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Enanta Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT07122661","title":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}